Eric Samuel Nisenbaum

Title: Eric Samuel Nisenbaum: Innovator in Pharmacology

Introduction: Eric Samuel Nisenbaum is an accomplished inventor based in Carmel, Indiana, known for his contributions to the field of pharmacology. With a focus on developing innovative treatments for mental health conditions, Nisenbaum's work has significant implications for the pharmaceutical industry.

Latest Patents: Nisenbaum holds a patent for 1-(hetero)aryl-3-amino-pyrrolidine derivatives that are utilized as mGluR3 antagonists. This invention is particularly relevant for treating conditions associated with mGluR3 receptors, including depression, schizophrenia, and migraines. The patent outlines the compounds’ formula and their pharmaceutical compositions, along with methods for their application.

Career Highlights: Currently, Nisenbaum is employed at Eli Lilly and Company, a major player in the pharmaceutical sector. His work there highlights his commitment to advancing medical science through innovative research and development efforts.

Collaborations: Throughout his career, Nisenbaum has collaborated with esteemed colleagues, including Thomas Charles Britton and Veronique Dehlinger. These partnerships foster a rich environment for sharing ideas and accelerating pharmaceutical innovations.

Conclusion: Eric Samuel Nisenbaum is a notable inventor whose work at Eli Lilly and Company focuses on groundbreaking treatments for mental health disorders. His patent on mGluR3 antagonists showcases his dedication to addressing challenging medical conditions, underscoring his impactful contributions to the field of pharmacology.